Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
-
May 12, 2022
Strong results highlighted by record first quarter revenue of $22.7 million and diluted EPS of $0.34 SALT LAKE CITY, May 12, 2022 /PRNewswire/ -- Co-Diagnostics, Inc. (NASDAQ: CODX), a molecular...
-
May 3, 2022
Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company" or "Co-Dx,"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today...
-
Apr 28, 2022
Co-Diagnostics, Inc. (Nasdaq: CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today it will release its first...
-
Apr 22, 2022
Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company" or "Co-Dx,"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today...
-
Apr 19, 2022
Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that CoSara...